Molecular Partners AG
HealthcareNASDAQ:MOLN · NASDAQ Global Select
+$0.40 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.7%
avg -32.8%
ROIC
-63.0%
avg -25.6%
ROA
-60.4%
avg -21.6%
Analysis
ROA is currently the strongest return metric at -60.4% versus its period average of -21.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Patrick Amstutz | Co-Founder, Chief Executive Officer, Member of Management Board & Director | $821,197.00 | — | 51 | — | — |
Alexander Zurcher | Chief Operating Officer & Member of Management Board | — | — | 51 | — | — |
Daniel Steiner | Senior Vice President of Targeted Radio Therapeutics | — | — | — | — | — |
Martin Steegmaier | Chief Scientific Officer & Member of the Management Board | — | — | 60 | — | — |
Michael Pitzner | Executive VP of Partnering & General Counsel | — | — | — | — | — |
Robert Hendriks | Senior VP of Finance & Member of Management Board | — | — | — | — | — |
Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | — | — | — | — | — |
Renate Gloggner | Executive Vice President of People & Community and Member of Management Board | — | — | 56 | — | — |
Pamela A. Trail | Strategic Consultant | — | — | 70 | — | — |
Philippe Legenne | Chief Medical Officer & Member of the Management Board | — | — | 60 | — | — |
Michael Tobias Stumpp | Co-Founder, Executive Vice President of Projects & Member of Management Board | — | — | 54 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -9.1% | +18.4% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -9.1% over three years. Forward estimates point to Revenue at +18.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages MOLN?
Molecular Partners AG (MOLN) lists 11 active executives. The top listed executive is Alexander Zurcher, Chief Operating Officer & Member of Management Board.
Explore More
Continue the stock analysis
Jump to another research area for this company.